Evidence map›Paper›PMID 33810229›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Filociclovir Is an Active Antiviral Agent against Ocular Adenovirus Isolates In Vitro and in the Ad5/NZW Rabbit Ocular Model.

Eric G Romanowski, Islam T M Hussein, Steven C Cardinale, Michelle M Butler, Lucas R Morin, Terry L Bowlin, Kathleen A Yates, Robert M Q Shanks, Regis P Kowalski

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Eric G RomanowskiThe Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0003-4246-3276
Islam T M HusseinMicrobiotix, Inc., Worcester, MA 01605, USA.
Steven C CardinaleMicrobiotix, Inc., Worcester, MA 01605, USA.
Michelle M ButlerMicrobiotix, Inc., Worcester, MA 01605, USA.
Lucas R MorinMicrobiotix, Inc., Worcester, MA 01605, USA.
Terry L BowlinMicrobiotix, Inc., Worcester, MA 01605, USA.
Kathleen A YatesThe Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0002-8995-8121
Robert M Q ShanksThe Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Regis P KowalskiThe Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0002-8558-0782
Microbiotix (United States) · USUniversity of Pittsburgh · US

Funding

Virus Production and Manipulation of Protein/Gene Expression ModuleP30EY008098 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Ethan A Rossi · 1989 to 2026
$17.8M
Development of Filociclovir for the Treatment of Ocular Adenoviral Infections and KeratoconjunctivitisR44EY032837 · NEI · MICROBIOTIX, INC · PI BOWLIN, TERRY L. · 2021 to 2022
$1.5M
Eye & Ear Foundation of Pittsburgh Dept. of Ophthalmology, University of PittsburghMicrobiotix, Inc. NoneNEI NIH HHS P30 EY008098NEI NIH HHS R44 EY032837NIH Core Grant for Vision Research EY08098Research to Prevent Blindness Dept. of Ophthalmology, University of Pittsburgh
6 · The paper itself

Abstract

Presently, there is no FDA- or EMA-approved antiviral for the treatment of human adenovirus (HAdV) ocular infections. This study determined the antiviral activity of filociclovir (FCV) against ocular HAdV isolates in vitro and in the Ad5/NZW rabbit ocular model. The 50% effective concentrations (EC

Indexed as

adenovirusanimal modelantiviralEKCeyefilociclovirin vitro

Identifiers

PMID33810229
PMCPMC8066960
OpenAlexW3151943940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.